- Home
- ARTV vs UNCY Comparison
ARTV vs UNCY Comparison
Compare ARTV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- UNCY
- Stock Information
- Founded
- ARTV 2019
- UNCY 2016
- Country
- ARTV United States
- UNCY United States
- Employees
- ARTV N/A
- UNCY 22
- Industry
- ARTV
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- ARTV
- UNCY Health Care
- Exchange
- ARTV NYSE
- UNCY Nasdaq
- Market Cap
- ARTV 61.9M
- UNCY 78.1M
- IPO Year
- ARTV 2024
- UNCY 2021
- Fundamental
- Price
- ARTV $2.08
- UNCY $0.55
- Analyst Decision
- ARTV Strong Buy
- UNCY Strong Buy
- Analyst Count
- ARTV 7
- UNCY 3
- Target Price
- ARTV $20.00
- UNCY $5.50
- AVG Volume (30 Days)
- ARTV 215.6K
- UNCY 567.3K
- Earning Date
- ARTV 05-08-2025
- UNCY 05-16-2025
- Dividend Yield
- ARTV N/A
- UNCY N/A
- EPS Growth
- ARTV N/A
- UNCY N/A
- EPS
- ARTV N/A
- UNCY N/A
- Revenue
- ARTV N/A
- UNCY N/A
- Revenue This Year
- ARTV N/A
- UNCY N/A
- Revenue Next Year
- ARTV N/A
- UNCY $1,502.84
- P/E Ratio
- ARTV N/A
- UNCY N/A
- Revenue Growth
- ARTV N/A
- UNCY N/A
- 52 Week Low
- ARTV $1.78
- UNCY $0.20
- 52 Week High
- ARTV $17.31
- UNCY $1.16
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- UNCY 39.05
- Support Level
- ARTV N/A
- UNCY $0.59
- Resistance Level
- ARTV N/A
- UNCY $0.66
- Average True Range (ATR)
- ARTV 0.00
- UNCY 0.04
- MACD
- ARTV 0.00
- UNCY -0.01
- Stochastic Oscillator
- ARTV 0.00
- UNCY 4.00
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.